CAPRISA 018: a phase I/II clinical trial study protocol to assess the safety, acceptability, tolerability and pharmacokinetics of a sustained-release tenofovir alafenamide subdermal implant for HIV prevention in women

INTRODUCTION: Young African women bear a disproportionately high risk for HIV acquisition. HIV technologies that empower women to protect themselves are needed. Safe, potent antiretroviral agents such as tenofovir alafenamide (TAF), formulated as long-acting subdermal implants, offer an innovative s...

Descripción completa

Detalles Bibliográficos
Autores principales: Gengiah, Tanuja Narayansamy, Abdool Karim, Quarraisha, Harkoo, Ishana, Mansoor, Leila, Zuma, Nonhlanhla Yende, Radebe, Precious, Samsunder, Natasha, Baxter, Cheryl, Maharaj, B, Baum, Marc M, Moss, John A, Pozzetto, Bruno, Hankins, Catherine, Abdool Karim, Salim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
HIV/AIDS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8739430/
https://www.ncbi.nlm.nih.gov/pubmed/34992111
http://dx.doi.org/10.1136/bmjopen-2021-052880

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8739430/
https://www.ncbi.nlm.nih.gov/pubmed/34992111
http://dx.doi.org/10.1136/bmjopen-2021-052880

Ejemplares similares